Nomura Holdings’s Ocular Therapeutix OCUL Stock Holding History

Nomura Holdings’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$424K	–	1981
2026 Q1	$424K	Buy	+50,000	New	+$477K	﹤0.01%	1410

Other funds holding OCUL

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nomura Holdings's OCUL Position: Q2 2026 in Review

Nomura Holdings sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 50,000 shares — an estimated $424K sold.

Nomura Holdings first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $424K in Q1 2026. 237 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Nomura Holdings reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 50,000 Ocular Therapeutix shares in Q2 2026, an estimated $424K.
Nomura Holdings first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
Nomura Holdings's Ocular Therapeutix position peaked at $424K in Q1 2026.
237 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.